Format

Send to

Choose Destination
Oncotarget. 2016 Apr 26;7(17):23106-27. doi: 10.18632/oncotarget.7145.

The emerging role of FTY720 (Fingolimod) in cancer treatment.

Author information

1
School of Medicine, Imperial College London, London, UK.
2
Department of Pharmacology and Biomedical Sciences, Faculty of Pharmacy and Medical Sciences, University of Petra, Amman, Jordan.
3
School of Medicine, University of East Anglia, Norwich, UK.
4
Department of Surgery and Cancer, Imperial College London, London, UK.

Abstract

FTY720 (Fingolimod) is a clinically approved immunomodulating therapy for multiple sclerosis that sequesters T-cells to lymph nodes through functional antagonism of sphingosine-1-phosphate 1 receptor. FTY720 also demonstrates a proven efficacy in multiple in vitro and in vivo cancer models, suggesting a potential therapeutic role in cancer patients. A potential anticancer mechanism of FTY720 is through the inhibition of sphingosine kinase 1, a proto-oncogene with in vitro and clinical cancer association. In addition, FTY720's anticancer properties may be attributable to actions on several other molecular targets. This study focuses on reviewing the emerging evidence regarding the anticancer properties and molecular targets of FTY720. While the clinical transition of FTY720 is currently limited by its immune suppression effects, studies aiming at FTY720 delivery and release together with identifying its key synergetic combinations and relevant patient subsets may lead to its rapid introduction into the clinic.

KEYWORDS:

FTY720; cancer; fingolimod; sphingolipid; sphingosine kinase

PMID:
27036015
PMCID:
PMC5029614
DOI:
10.18632/oncotarget.7145
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center